-
Larimar Therapeutics Reports Positive Results
Larimar issued a press release to discuss the topline data from its Phase 1 multiple ascending dose (MAD) clinical trial (n=27) evaluating CTI-1601 as a treatment for FA in a call this morning at 8am (ET). Data show that repeated subcutaneous administration of CTI-1601 resulted in dose-dependent increases in frataxin (FXN) levels from baseline compared to placebo controls. These dose-dependent increases in frataxin levels were seen in all evaluated tissues with daily dosing.
The company anticipates initiation of an open-label extension clinical trial for patients who completed the single ascending dose (SAD) and/or MAD clinical trials in the second half of 2021. Larimar also expects to initiate a MAD clinical trial in patients under 18 years of age in the second half of 2021.
To read the full press release or for information on how to join the call, visit: https://investors.larimartx.com/news-releases/news-release-details/larimar-therapeutics-reports-positive-topline-phase-1-clinical
-
0 Replies
Sorry, there were no replies found.
Log in to reply.